Investors sold shares of Gilead Sciences, Inc. (NASDAQ:GILD) on strength during trading hours on Tuesday. $73.22 million flowed into the stock on the tick-up and $133.00 million flowed out of the stock on the tick-down, for a money net flow of $59.78 million out of the stock. Of all companies tracked, Gilead Sciences had the 19th highest net out-flow for the day. Gilead Sciences traded up $0.38 for the day and closed at $72.51
A number of research analysts have issued reports on GILD shares. BidaskClub upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. Leerink Swann restated a “hold” rating and set a $74.00 price target on shares of Gilead Sciences in a research note on Tuesday, July 25th. Robert W. Baird restated an “outperform” rating and set a $87.00 price target on shares of Gilead Sciences in a research note on Tuesday, July 25th. Redburn Partners started coverage on shares of Gilead Sciences in a research note on Wednesday, July 26th. They set a “buy” rating on the stock. Finally, J P Morgan Chase & Co set a $85.00 price target on shares of Gilead Sciences and gave the company an “overweight” rating in a research note on Thursday, July 27th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. Gilead Sciences presently has an average rating of “Buy” and a consensus price target of $84.87.
The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. The stock has a market cap of $94,690.00, a P/E ratio of 7.56, a price-to-earnings-growth ratio of -1.21 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company’s revenue for the quarter was down 13.2% on a year-over-year basis. During the same period last year, the firm posted $2.75 earnings per share. analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.87%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.66%.
In other Gilead Sciences news, CFO Robin L. Washington sold 51,820 shares of Gilead Sciences stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the transaction, the chief financial officer now directly owns 43,352 shares of the company’s stock, valued at $3,684,920. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John F. Milligan sold 220,000 shares of Gilead Sciences stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. Insiders have sold 666,819 shares of company stock worth $52,303,086 over the last ninety days. 1.30% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently made changes to their positions in GILD. Capital International Investors increased its position in shares of Gilead Sciences by 86.6% during the third quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock valued at $908,803,000 after acquiring an additional 5,205,983 shares during the last quarter. Sanders Capital LLC acquired a new stake in shares of Gilead Sciences during the third quarter valued at about $427,585,000. Skandinaviska Enskilda Banken AB publ increased its position in shares of Gilead Sciences by 230.0% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 4,927,585 shares of the biopharmaceutical company’s stock valued at $399,233,000 after acquiring an additional 3,434,450 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Gilead Sciences by 35.0% during the second quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock valued at $736,667,000 after acquiring an additional 2,700,600 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its position in shares of Gilead Sciences by 84.7% during the third quarter. Ameriprise Financial Inc. now owns 5,505,708 shares of the biopharmaceutical company’s stock valued at $446,197,000 after acquiring an additional 2,524,657 shares during the last quarter. Institutional investors and hedge funds own 76.30% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.